相关实验视频

Updated: Jun 12, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

对患有晚期胆道癌症的患者进行综合基因组分析测试的临床用处

Hiroki Inada^1,2, Hideaki Miyamoto^1,2, Satoru Shinriki^2,3

¹Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.

International journal of clinical oncology

|September 19, 2024

概括

综合性基因组分析确定了胆道癌症中可操作的FGFR2融合. 佩米加替尼在这些融合的肝脏内胆管癌患者中表现出有效性和耐受性,改善了整体存活率.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
精准医学是一门精准的医学.

背景情况:

胆道癌 (BTC) 由于治疗选择有限,预后不佳.
下一代测序和综合基因组分析 (CGP) 在临床实践中越来越多地使用.

研究的目的:

评估CGP在BTC中识别可采取行动的突变中的实用性.
评估基于CGP结果的向疗法的疗效和安全性.

主要方法:

追溯的,多中心的观察队列研究.
分析了接受CGP的85名BTC患者的基因组和临床数据.
评估治疗建议和药物可用性.

主要成果:

在73%的病例中提出了治疗建议.
药物可获得率为15.3% (13名患者).
五名患有FGFR2融合的肝内胆管癌 (ICC) 患者接受了佩米加替尼,与未接受基因组匹配疗法 (NR vs 8.6 个月) 患者相比,他们的整体存活时间明显更长.
佩米加提尼布治疗导致了3名患者的部分反应,1名患者的稳定疾病,1名患者的进展性疾病,中位数无进展生存时间为9.0个月.
没有观察到需要停止治疗的3/4级不良事件.

结论:

综合性基因组分析对于确定BTC中的治疗点是有价值的.
佩米加替尼在患有FGFR2基因融合的ICC患者中有效且耐受良好.
观察到,对于具有可操作突变的ICC患者来说,药物可获得性很高.

关键词:

胆道癌是一种胆道癌症.综合性基因组分析分析在FGFR2核聚变.基因组匹配疗法是一种基因组匹配疗法.佩米加替尼布 (pemigatinib) 的使用情况

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...